Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSOLIDATE: Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer
NCT06434350Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in bladder cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression Free Survival, Safety and adverse events at 1 year and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06434350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434350.